Rytmonorm 150mg 50 tablets — Made in Germany — Free Delivery

Brand: Abbott Laboratories GmbH
Product Code: Rytmonorm 150mg
Availability: In Stock

$54.55

Add to Cart

Description

Product description

Rytmonorm® tablets are used for the prevention and treatment of:

ventricular arrhythmias;
paroxysmal supraventricular tachyarrhythmias, including paroxysmal atrial flutter / fibrillation and paroxysmal reentry tachycardia involving the AV node or additional pathways, with the ineffectiveness of standard therapy or contraindications for its implementation.

Compound

The active substance is propafenone hydrochloride (one tablet contains propafenone hydrochloride 150 mg).

Excipients: microcrystalline cellulose, croscarmellose sodium, corn starch, hypromellose, magnesium stearate, purified water, macrogol 400, macrogol 6000, titanium dioxide (E 171).

Contraindications

hypersensitivity to propafenone hydrochloride or to any other component of the preparation indicated in the "Composition" section;
discovered Brugada syndrome;
a case of myocardial infarction in the last 3 months;
significant organic heart disease such as:
uncontrolled congestive heart failure (left ventricular ejection fraction < 35%);
cardiogenic shock (if it is not caused by arrhythmia);
severe symptomatic bradycardia;
sinus node dysfunction, atrial conduction disturbances, second-degree or higher AV block, bundle block, or distal block in the absence of an artificial pacemaker;
severe arterial hypotension;
manifest electrolyte disturbances (for example, a violation of potassium metabolism);
severe obstructive pulmonary disease;
simultaneous use with ritonavir;
myasthenia gravis;
severe liver failure.

Mode of application

Therapy with the preparation "Rytmonorm®" is recommended to be started in a hospital setting, it should be carried out by a doctor who has experience in the treatment of arrhythmias. The individual maintenance dose should be determined under cardiac surveillance, including ECG monitoring and blood pressure monitoring. If the QRS complex increases by more than 20%, the dose should be reduced or the dose discontinued until the ECG returns to normal.

Due to the bitter taste and surface anesthetic effect of propafenone, tablets should be swallowed whole (not chewed) with liquid.

Use for adults inside at the beginning of treatment - 150 mg 3 times a day with an increase in dose with a minimum of a three-day interval up to 300 mg 2 times a day and, if necessary, up to a maximum dose of 300 mg 3 times a day. Increasing the dose is possible not earlier than after 3-4 days of treatment. For patients weighing less than 70 kg, it is recommended to prescribe daily doses that are less than usual, individually.

Application features

pregnant

Animal studies have not shown a teratogenic effect. Adequate and well-controlled studies of the use of this preparation during pregnancy are not available, therefore, Rytmonorm® should be used during this period only when the potential benefit from the use outweighs the potential risk to the fetus. Propafenone hydrochloride is known to cross the placental barrier in humans. It was reported that the concentration of propafenone in umbilical cord blood was 30% of its concentration in maternal blood.

Studies on the excretion of propafenone hydrochloride in breast milk have not been conducted. Limited data suggest that propafenone may pass into breast milk. Women who are breastfeeding should use propafenone hydrochloride with caution.

Children

Rytmonorm® tablets are not used for children.

Drivers

It should be borne in mind that in sensitive patients, when using the preparation , adverse reactions may occur (blurred vision, dizziness, weakness, orthostatic hypotension), which can affect the patient's reaction rate and impair his ability to drive vehicles or other mechanisms and perform work that requires concentration of attention. .

Overdose

Cardiac symptoms of overdose

The effect of an overdose of propafenone hydrochloride on the myocardium is manifested by disturbances in impulse generation and conduction, such as PQ prolongation, widening of the QRS complex, inhibition of sinus node automatism, AV block, ventricular tachycardia, ventricular flutter / fibrillation and cardiac arrest. A decrease in cardiac contractility (negative inotropic effect) can cause hypotension, which in severe cases can lead to cardiovascular shock.

Non-cardiac signs and symptoms of overdose

Metabolic acidosis, headache, dizziness, blurred vision, paresthesia, tremors, nausea, constipation, dry mouth and convulsions have been reported in overdose. There was also a death report.

In case of severe poisoning, clonic-tonic convulsions, paresthesia, drowsiness, coma and respiratory arrest may develop.

Treatment

Due to the high degree of binding to blood proteins (> 95%) and the large volume of distribution, hemodialysis is ineffective; attempts at elimination by hemoperfusion are ineffective.

In addition to the application of general emergency measures, it is necessary to monitor the patient's vital signs in the intensive care unit and, if necessary, to correct them.

Effective measures to control rhythm and blood pressure are defibrillation and infusion of dopamine and isoproterenol. To relieve seizures, diazepam is administered.

General supportive measures such as mechanical ventilation and chest compressions may be required.

Side effects

Frequent and common adverse reactions associated with propafenone therapy are dizziness, cardiac conduction disturbances, and palpitations.

Storage conditions

Store at a temperature not exceeding 25 ° C, out of the reach of children.

Shelf life - 3 years.

0 reviews

There are no reviews for this product.